PubRank

N Brünner

Author PubWeight™ 116.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 1992 3.15
2 The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000 2.09
3 High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993 1.86
4 Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999 1.86
5 Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998 1.65
6 Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999 1.64
7 Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000 1.58
8 Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994 1.55
9 Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000 1.48
10 The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998 1.38
11 Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 2000 1.31
12 Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994 1.28
13 High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000 1.27
14 Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996 1.27
15 ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997 1.26
16 Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999 1.24
17 Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005 1.24
18 Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993 1.23
19 Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993 1.22
20 Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995 1.19
21 Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A 1989 1.19
22 Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999 1.15
23 Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 1999 1.14
24 Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999 1.10
25 A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994 1.04
26 Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 1997 1.03
27 TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006 1.02
28 Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995 1.01
29 Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 1998 1.01
30 The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 1993 0.99
31 Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001 0.99
32 Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2002 0.99
33 Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 1993 0.99
34 Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001 0.99
35 External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998 0.99
36 Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. Clin Exp Metastasis 1998 0.97
37 Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 1996 0.97
38 Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion 1996 0.96
39 Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler 1995 0.96
40 Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer 1998 0.96
41 Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol 1998 0.95
42 S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001 0.95
43 Effect of 17 beta-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. Br J Cancer 1983 0.95
44 The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol Endocrinol 1989 0.95
45 Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 1998 0.94
46 Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 2003 0.94
47 The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998 0.94
48 The process of malignant progression in human breast cancer. Ann Oncol 1990 0.93
49 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994 0.92
50 Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer 1998 0.91
51 Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997 0.91
52 Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. Int J Cancer 1994 0.91
53 Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice. Acta Pathol Microbiol Immunol Scand A 1986 0.91
54 A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. Mol Endocrinol 1990 0.90
55 Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol Chem 2001 0.90
56 Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997 0.89
57 Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. Clin Exp Metastasis 1992 0.89
58 Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1985 0.89
59 Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep 2005 0.88
60 The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. Acta Oncol 1992 0.87
61 Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients. Scand J Immunol 2005 0.87
62 In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 1998 0.87
63 Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2004 0.87
64 Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer 1999 0.87
65 Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. Eur J Cancer 2004 0.87
66 Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor driven phenotypes? Trends Endocrinol Metab 1996 0.86
67 Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002 0.86
68 Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 1997 0.86
69 High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study. Cancer Biomark 2007 0.85
70 The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000 0.85
71 Histologic changes following oestradiol treatment of a hormone-responsive human breast carcinoma grown in nude mice. Acta Pathol Microbiol Immunol Scand A 1982 0.85
72 Leucocyte-derived bioactive substances in fresh frozen plasma. Br J Anaesth 1997 0.84
73 Differential gene expression in human mammary carcinoma cells: identification of a new member of a receptor family. Anticancer Res 1997 0.83
74 Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001 0.83
75 Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 2007 0.83
76 Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001 0.83
77 Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003 0.83
78 Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 2001 0.83
79 ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. Int J Cancer 1997 0.83
80 The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer. J Endocrinol 1989 0.82
81 Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. Ann Oncol 2010 0.82
82 Disaggregation of human solid tumours by combined mechanical and enzymatic methods. Br J Cancer 1985 0.82
83 Characterization of the T61 human breast carcinoma established in nude mice. Eur J Cancer Clin Oncol 1985 0.82
84 Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 1994 0.82
85 Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis 1998 0.81
86 Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotech Histochem 1994 0.81
87 Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 1996 0.81
88 Acquisition of an antiestrogen-resistant phenotype in breast cancer: role of cellular and molecular mechanisms. Cancer Treat Res 1996 0.81
89 Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer. Colorectal Dis 2006 0.81
90 Dose-dependent effect of 17 beta-estradiol determined by growth curves and flow cytometric DNA analysis of a human breast carcinoma (T61) grown in nude mice. Exp Cell Biol 1985 0.80
91 Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer 2001 0.80
92 Growth inhibition in response to estrogen withdrawal and tamoxifen therapy of human breast cancer xenografts evaluated by in vivo 31P magnetic resonance spectroscopy, creatine kinase activity, and apoptotic index. Cancer Res 1995 0.80
93 Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. Eur J Cancer Clin Oncol 1985 0.80
94 Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231. APMIS 1994 0.79
95 Serum steroid levels in intact and endocrine ablated BALB/c nude mice and their intact littermates. J Steroid Biochem 1986 0.79
96 Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer. Scand J Clin Lab Invest 2007 0.79
97 Soluble urokinase plasminogen activator receptor in blood transfusion components. Transfus Med 2004 0.79
98 Identification of two estrogen regulated genes associated with growth regulation of human breast cancer. Mol Cell Endocrinol 2001 0.78
99 Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998 0.78
100 Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies. Clin Exp Metastasis 2004 0.78
101 Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 2009 0.78
102 Immunoreactive opioid peptides in human breast cancer. Am J Pathol 1989 0.78
103 Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 2005 0.77
104 Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7/LCC1 and MCF-7/LCC2. J Steroid Biochem Mol Biol 1998 0.77
105 Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int J Biol Markers 2005 0.77
106 Loss of ELISA specificity due to biotinylation of monoclonal antibodies. J Immunol Methods 2000 0.77
107 Migratory, invasive and metastatic capacity of NCAM transfected rat glioma cells. Int J Dev Neurosci 1993 0.77
108 Leucocyte and platelet-derived bioactive substances in stored blood: effect of prestorage leucocyte filtration. Eur J Haematol 1997 0.77
109 Identifying sources and estimating glandular output of salivary TIMP-1. Scand J Clin Lab Invest 2008 0.77
110 p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. Clin Cancer Res 1996 0.77
111 Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. Breast Cancer Res Treat 2001 0.77
112 Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A. Eur J Cancer 1994 0.76
113 Dissemination in athymic nude mice of lacZ transfected small cell lung cancer cells identified by X-gal staining. APMIS 1995 0.76
114 Effect of estrogen withdrawal on energy-rich phosphates and prediction of estrogen dependence monitored by in vivo 31P magnetic resonance spectroscopy of four human breast cancer xenografts. Cancer Res 1995 0.76
115 Cytokeratin-positive cells in preoperative peripheral blood and bone marrow aspirates of patients with colorectal cancer. Scand J Clin Lab Invest 2002 0.76
116 Effect of NCAM-transfection on growth and invasion of a human cancer cell line. APMIS 1997 0.76
117 Growth kinetics of four human breast carcinomas grown in nude mice. Breast Cancer Res Treat 1989 0.76
118 Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. Int J Biol Markers 2006 0.76
119 Plasma Escherichia coli beta-galactosidase as a marker of tumor burden and response to experimental anti-neoplastic therapy in nude mice xenografted with lacZ transduced human tumor cells. Lab Invest 2000 0.75
120 Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue. Mol Oncol 2007 0.75
121 Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates. Eur J Haematol 1996 0.75
122 A new immunocapture assay for Escherichia coli beta-galactosidase for in vivo studies of lacZ-transduced tumor cells. Lab Invest 1998 0.75
123 The use of the CELLection kit in the isolation of carcinoma cells from mononuclear cell suspensions. J Immunol Methods 2000 0.75
124 The plasminogen activation system and its role in lung cancer. A review. Lung Cancer 1995 0.75
125 Oestrogen receptor assay. False positive analysis? Acta Radiol Oncol 1984 0.75
126 Investigations on hormone dependency of human mammary carcinomas transplanted into nude mice. Acta Obstet Gynecol Scand Suppl 1981 0.75
127 [Value of mammography in the diagnosis of breast cancer]. Ugeskr Laeger 1978 0.75
128 Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude mice. Int J Cancer 1985 0.75
129 Genetic analysis of a metastasizing substrain of nude mice. Folia Microbiol (Praha) 1998 0.75
130 Mendelian analysis of a metastasis-prone substrain of BALB/c nude mice using a subcutaneously inoculated human tumour. APMIS 2006 0.75
131 Effect of melphalan on growth curves and cell cycle distribution of four human small cell carcinomas of the lung grown in nude mice. Exp Cell Biol 1986 0.75
132 [Breast cancer and polypeptide growth factors]. Nord Med 1992 0.75
133 Secondary surgery in advanced testicular germ-cell tumors. Scand J Urol Nephrol 1983 0.75
134 Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients. Clin Chem 1999 0.75
135 Detection of endocrine responsiveness by flow cytometric DNA analysis in experimental human breast cancer. Recent Results Cancer Res 1984 0.75
136 The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Immunol Methods 1997 0.75
137 Marker of erosive progression in RA. Ann Rheum Dis 2000 0.75
138 Comparison of the effect of cortisol on aromatase activity and androgen metabolism in two human fibroblast cell lines derived from the same individual. J Steroid Biochem 1990 0.75
139 Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. Eur J Cancer 2003 0.75